<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00209287</url>
  </required_header>
  <id_info>
    <org_study_id>Mesalazine 2004-01</org_study_id>
    <nct_id>NCT00209287</nct_id>
  </id_info>
  <brief_title>Study of Effects and of Modifications in Apoptosis Regulators Observed After Stopping 5-ASA Treatment in Patients With Inactive Ulcerative Colitis</brief_title>
  <official_title>Study of Histological Modifications, of Pro-apoptotic Effects and of Modifications in Apoptosis Regulators Observed After Stopping 5-ASA Treatment in Patients With Inactive Ulcerative Colitis (Clinical and Endoscopic Remission) Taking 5-ASA</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ferring Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ferring Pharmaceuticals</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Male or female, 18 years of age or older. Ulcerative Colitis described according usual
      criteria, diagnosed for at least 1 year. Oral maintenance treatment with 5-aminosalicylic
      acid (5-ASA) only for at least 3 months with a dosage of 2 to 3 g/day. Clinical remission for
      at least 3 months (Mayo Clinic score) and endoscopic remission (endoscopic score of Mayo
      Clinic) at the inclusion. Signed informed consent form.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Inclusion Criteria:

        -  Male or female, 18 years of age or older.

        -  Ulcerative colitis described according to usual criteria, diagnosed for at least 1 year.

        -  Oral maintenance treatment with 5-aminosalicylic acid (5-ASA) only for at least 3 months
           with a dosage of 2 to 3 g/day.

        -  Clinical remission for at least 3 months (Mayo Clinic score) and endoscopic remission
           (endoscopic score of Mayo Clinic) at inclusion.

        -  Signed informed consent form.

      Exclusion Criteria:

        -  Patients allergic to aspirin or salicylates derivatives

        -  Patients taking the following treatments during the study will be excluded:
           corticosteroids (oral or rectal route), use of NSAID or Aspirin, any form of
           sulfasalazine, mesalazine or 4-ASA.

        -  Patients with known significant hepatic or known function abnormalities and/or creatine
           clearance ≤ 80 ml/min.

        -  Patients with history or physical examination findings indicative of active alcohol or
           drug abuse.

        -  Women who are pregnant or nursing.

        -  Patients with a history of disease, including mental/emotional disorder that would
           interfere with their participation in the study.

        -  Patients who participated in another clinical study in the last 3 months.

        -  Patients who are unable to comply with the requirements of the protocol

        -  Female of childbearing potential without efficacious contraception.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Recruitment problematic
  </why_stopped>
  <start_date>June 2005</start_date>
  <completion_date type="Actual">September 2007</completion_date>
  <primary_completion_date type="Actual">December 2006</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change between rectal biopsies performed at D1 and D28 of proliferative index</measure>
    <time_frame>Its aim was to study histological modifications after Pentasa was stopped in non-active ulcerative colitis.</time_frame>
  </primary_outcome>
  <enrollment type="Actual">6</enrollment>
  <condition>Ulcerative Colitis</condition>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Observe patients with inactive ulcerative colitis</intervention_name>
    <description>Observe patients with inactive ulcerative colitis</description>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female, 18 years of age or older.

          -  Ulcerative colitis described according to usual criteria, diagnosed for at least 1
             year.

          -  Oral maintenance treatment with 5-ASA only for at least 3 months with a dosage of 2 to
             3 g/day.

          -  Clinical remission for at least 3 months (Mayo Clinic score) and endoscopic remission
             (endoscopic score of Mayo Clinic) at inclusion.

          -  Signed informed consent form.

        Exclusion Criteria:

          -  Patients allergic to aspirin or salicylates derivatives

          -  Patients taking the following treatments during the study will be excluded:
             corticosteroids (oral or rectal route), use of NSAID or Aspirin, any form of
             sulfasalazine, mesalazine or 4-ASA.

          -  Patients with known significant hepatic or known function abnormalities and/or
             creatine clearance ≤ 80 ml/min.

          -  Patients with history or physical examination findings indicative of active alcohol or
             drug abuse.

          -  Women who are pregnant or nursing.

          -  Patients with a history of disease, including mental/emotional disorder that would
             interfere with their participation in the study.

          -  Patients who participated in another clinical study in the last 3 months.

          -  Patients who are unable to comply with the requirements of the protocol

          -  Female of childbearing potential without efficacious contraception.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Development Support</last_name>
    <role>Study Director</role>
    <affiliation>Ferring Pharmaceuticals</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hôpital Saint Antoine, Service d'hépato-Gastroentérologie</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>April 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 13, 2005</study_first_submitted>
  <study_first_submitted_qc>September 19, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 21, 2005</study_first_posted>
  <last_update_submitted>April 20, 2012</last_update_submitted>
  <last_update_submitted_qc>April 20, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 23, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Ulcerative Colitis for Maintenance of Remission</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colitis</mesh_term>
    <mesh_term>Ulcer</mesh_term>
    <mesh_term>Colitis, Ulcerative</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

